Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Evaluate Safety of Tramadol in the Management of Postoperative Pain Following Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03395808
Recruitment Status : Completed
First Posted : January 10, 2018
Results First Posted : March 9, 2021
Last Update Posted : March 9, 2021
Information provided by (Responsible Party):
Avenue Therapeutics, Inc.

Brief Summary:
The study evaluates the safety of IV tramadol managing post-operative pain following surgery.

Condition or disease Intervention/treatment Phase
Pain Management Drug: Tramadol Phase 3

Detailed Description:
(Non-clinical summary) Tramadol is a centrally-acting synthetic analgesic of the aminocyclohexanol group with opioidlike effects. Tramadol is extensively metabolized following administration, which results in a number of enantiomeric metabolites that display different opioid-receptor binding properties, and monoaminergic reuptake inhibition.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 251 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 3, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety of Tramadol Infusion (AVE-901) in the Management of Post-Operative Pain Following Surgery
Actual Study Start Date : December 22, 2017
Actual Primary Completion Date : April 25, 2019
Actual Study Completion Date : May 6, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Tramadol

Arm Intervention/treatment
AVE-901 50mg
IV Tramadol
Drug: Tramadol
IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: Up to 21 days ]
    Reported Adverse Events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • The patient is male or female 18-75 years of age
  • Willing to give consent and able to understand the study procedures
  • Female patients must be of non-childbearing potential or be practicing a highly effective contraption
  • The patient must be willing to be housed in a healthcare facility and able to receive parenteral analgesia for at least 24 hours after surgery
  • The patient meets definition of American Society of Anesthesiologists (ASA) Physical Class 1, or 2.

Exclusion Criteria:

  • The patient has used chronic opioid therapy, defined as >= 20 MEQs of morphine per day >=3 days out of 7 days over the past 4 weeks.
  • The patient has a recent (within 2 years) and/or current history of alcohol, opiate or tranquilizer abuse or dependence.
  • The patient is taking herbal or dietary supplements or medications that are moderate or strong inhibitors of CYP2D6 or CYP3A4 (e.g., fluoxetine, paroxetine, amitriptyline, quinidine, ketoconazole, erythromycin, grapefruit juice) or inducers of CYP3A4 (e.g., carbamazepine, rifampin, St. John's Wort) and cannot go through a minimum washout period of 7 days prior to surgery.
  • The patient has a history of epilepsy, is susceptible to seizures.
  • The patient cannot be withdrawn from medications (at least 7 days prior to surgery) that may lower the seizure threshold (e.g. anti-psychotic agents, MAOI inhibitors) or which increase serotonergic tone (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans, amphetamines).
  • The patient has had a recent (within 6 months) cardiovascular event or clinically significant abnormal ECG finding at screening.
  • The patient has a history of Long QT Syndrome or a relative with this condition.
  • The patient has expressed suicidal ideation within the past 3 months or is considered to be at risk of suicide.
  • The patient is morbidly obese (body mass index [BMI] ≥ 40 kg/m2) or has documented sleep apnea requiring CPAP or other treatment.
  • Female patient is pregnant and/or undergoing a pregnancy-related surgery, or breastfeeding.
  • The patient has a history of cardiopulmonary, neurological or psychiatric condition that may confound the assessments of efficacy or safety.
  • The patient has cirrhosis, moderate or severe hepatic impairment or an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value > 3X upper limit of normal (ULN) at Screening.
  • The patient has severe renal impairment or a serum creatinine value of > 2x upper limit of normal (ULN) at Screening.
  • The patient has potassium, sodium, calcium or magnesium levels outside of the normal range at Screening.
  • The patient has a hemoglobin level at screening which, in the judgment of the Investigator, is not suitable for participation in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03395808

Layout table for location information
United States, California
Lotus Clinical Research
Pasadena, California, United States, 91105
Sponsors and Collaborators
Avenue Therapeutics, Inc.
  Study Documents (Full-Text)

Documents provided by Avenue Therapeutics, Inc.:
Study Protocol  [PDF] August 29, 2018
Statistical Analysis Plan  [PDF] February 7, 2019

Layout table for additonal information
Responsible Party: Avenue Therapeutics, Inc. Identifier: NCT03395808    
Other Study ID Numbers: AVE-901-104
First Posted: January 10, 2018    Key Record Dates
Results First Posted: March 9, 2021
Last Update Posted: March 9, 2021
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents